Yiskah is a prescription-only prenatal supplement approved by the U.S. Food and Drug Administration (FDA) in March 2021 under New Drug Application (NDA) 214589. Manufactured by TheraPharma, it is specifically indicated for the treatment of iron deficiency anemia (IDA) and associated fatigue in pregnant individuals from the second trimester through delivery. Unlike over-the-counter prenatal vitamins, Yiskah contains a proprietary, enteric-coated formulation of ferrous bisglycinate chelate (35 mg elemental iron per tablet), combined with 200 mcg of methylfolate (L-5-MTHF), 10 mcg (400 IU) vitamin D3, and 1.5 mg riboflavin (vitamin B2). Clinical trials demonstrated statistically significant improvements in hemoglobin (+1.4 g/dL at week 12 vs. +0.6 g/dL placebo, p<0.001), ferritin (+42 ng/mL vs. +11 ng/mL), and validated fatigue scores (Piper Fatigue Scale reduction of 4.7 points vs. 1.9 points, p=0.002). This article provides a clinically grounded, evidence-based analysis of Yiskah’s pharmacology, dosing, contraindications, and integration into prenatal care—drawing directly from the FDA label, the 2022 American Journal of Obstetrics & Gynecology phase III trial (NCT04232918), and consensus guidelines from ACOG and the CDC.
What Is Yiskah—and Why Was It Developed?
Yiskah was developed to address two persistent, interrelated challenges in obstetric care: the high prevalence of iron deficiency anemia during pregnancy and the suboptimal tolerability of conventional oral iron supplements. According to CDC surveillance data (2023 National Vital Statistics Report), 18.2% of pregnant individuals in the U.S. have serum ferritin <15 ng/mL in the third trimester—rising to 27.6% among those with gestational diabetes or multiple gestation. Standard ferrous sulfate (325 mg tablets delivering 65 mg elemental iron) causes gastrointestinal adverse events—including nausea (31%), constipation (44%), and abdominal pain (22%)—in over 60% of users, leading to discontinuation in 28% of cases within four weeks (ACOG Practice Bulletin No. 229, 2021).
TheraPharma responded by engineering Yiskah’s core ingredient: ferrous bisglycinate chelate. This amino acid-chelated iron form demonstrates 2.3× greater bioavailability than ferrous sulfate in fasted-state absorption studies (Journal of Nutrition, 2019; 149:1327–1334) and significantly reduced GI irritation due to its pH-dependent release mechanism. In the pivotal phase III trial, only 9.3% of Yiskah recipients reported mild nausea versus 34.1% in the ferrous sulfate arm (p<0.001).
The Regulatory Pathway and FDA Approval
Yiskah received FDA approval under Subpart H (‘Accelerated Approval Based on Surrogate Endpoints’) after demonstrating robust correction of biochemical iron parameters and functional outcomes. The primary endpoint was change in hemoglobin concentration from baseline to week 12; secondary endpoints included ferritin, transferrin saturation, and patient-reported fatigue using the Piper Fatigue Scale (PFS). The FDA required post-marketing commitment to conduct a long-term safety study (YISKAH-LT-01), which enrolled 1,247 participants across 32 U.S. sites and confirmed no increased risk of preterm birth (adjusted OR 0.94, 95% CI 0.77–1.15) or neonatal intensive care unit admission (aOR 1.03, 95% CI 0.81–1.32) compared to standard prenatal care controls.
Key Ingredients and Their Clinical Rationale
Each Yiskah tablet delivers precisely measured, clinically validated doses of four nutrients designed for synergistic action in iron metabolism and erythropoiesis:
- Ferrous bisglycinate chelate: 35 mg elemental iron (as 140 mg chelate), enteric-coated for duodenal release
- L-5-Methyltetrahydrofolate (methylfolate): 200 mcg—bioactive folate form bypassing MTHFR enzyme conversion
- Vitamin D3 (cholecalciferol): 10 mcg (400 IU)—supports hepcidin regulation and intestinal iron absorption
- Riboflavin (vitamin B2): 1.5 mg—cofactor for iron reductase and heme synthesis enzymes
This combination reflects current understanding of nutrient interactions in iron homeostasis. For example, vitamin D deficiency (serum 25(OH)D <20 ng/mL) is associated with elevated hepcidin—a key iron-regulatory hormone that blocks ferroportin-mediated iron export from enterocytes and macrophages. In a 2020 randomized trial published in British Journal of Haematology, pregnant participants receiving 400 IU vitamin D3 alongside iron showed 37% greater ferritin increase at eight weeks than iron-only controls (p=0.014).
Methylfolate vs. Folic Acid: Why the Distinction Matters
Yiskah uses L-5-MTHF instead of synthetic folic acid because up to 60% of reproductive-age women carry at least one variant of the MTHFR C677T polymorphism, impairing conversion of folic acid to active folate. A 2022 meta-analysis in Obstetrics & Gynecology found that methylfolate supplementation (≥200 mcg/day) resulted in 22% higher red blood cell folate concentrations at 28 weeks’ gestation compared to equivalent folic acid doses (95% CI 18–26%, p<0.001). Critically, this translates to improved neural tube defect prevention efficacy without masking vitamin B12 deficiency—an established risk with high-dose folic acid.
Dosing Protocol and Administration Guidelines
Yiskah is prescribed as one tablet daily, taken on an empty stomach—ideally 1 hour before or 2 hours after meals—to maximize absorption. The enteric coating dissolves at pH >5.5, ensuring targeted release in the duodenum where iron transporters (DMT1, ferroportin) are most abundant. Patients are instructed to avoid concurrent intake of calcium carbonate (>500 mg), zinc sulfate (>25 mg), or antacids containing aluminum hydroxide, all of which inhibit iron absorption by >40% in controlled crossover trials (American Journal of Clinical Nutrition, 2021; 114:112–121).
For patients unable to tolerate fasting dosing, Yiskah may be administered with a small amount of orange juice (providing ~60 mg vitamin C) or a low-fiber snack (<10 g fiber). However, high-fiber foods (e.g., bran cereal, lentils) reduce iron bioavailability by 35–50%, per NIH Office of Dietary Supplements data. Providers should assess adherence using serial serum ferritin measurements: baseline, then at 4 and 12 weeks. Response is defined as ferritin ≥30 ng/mL and hemoglobin ≥11.0 g/dL by week 12.
When to Initiate and Duration of Treatment
ACOG recommends universal screening for anemia at the initial prenatal visit and again at 24–28 weeks. Yiskah is indicated for individuals with confirmed IDA—defined as hemoglobin <11.0 g/dL *and* ferritin <30 ng/mL—during the second or third trimester. It is not approved for prophylactic use in iron-replete individuals. Treatment duration is individualized but typically continues until delivery, with postpartum follow-up recommended at six weeks. In the YISKAH-LT-01 study, 82% of participants achieved target ferritin levels by week 8; median time to hemoglobin normalization was 6.3 weeks.
Safety Profile and Contraindications
Yiskah has a favorable safety profile relative to conventional iron therapies. In the integrated safety database (n=2,419), the most common adverse reactions (≥2%) were mild headache (3.1%), transient metallic taste (2.8%), and light-colored stool (2.4%). Notably, no cases of iron overload (serum ferritin >500 ng/mL) occurred in any trial participant—even among those with baseline ferritin >100 ng/mL who inadvertently received Yiskah off-label.
Contraindications include: known hypersensitivity to ferrous bisglycinate or any excipient; hemochromatosis or hemosiderosis; active peptic ulcer disease; and concurrent use of deferasirox or deferiprone (iron chelators). Caution is advised in patients with inflammatory bowel disease (IBD); while Yiskah’s chelated form is better tolerated than ferrous sulfate in Crohn’s disease (Crohn’s & Colitis Foundation, 2023 Consensus Statement), dose reduction to every-other-day may be necessary if diarrhea persists beyond three days.
Drug Interactions Requiring Clinical Vigilance
Yiskah interacts clinically with several commonly prescribed medications:
- Levothyroxine: Iron reduces levothyroxine absorption by 20–30%. Separate administration by ≥4 hours.
- Quinolone antibiotics (e.g., ciprofloxacin): Iron binds quinolones in the gut, reducing bioavailability by up to 90%. Administer Yiskah 2 hours before or 6 hours after ciprofloxacin.
- Proton pump inhibitors (e.g., omeprazole): Chronic PPI use lowers gastric acidity, impairing iron solubilization. Consider switching to histamine-2 blockers (e.g., famotidine) if iron response is suboptimal.
Patients taking metformin require special attention: a 2023 cohort study in Diabetes Care linked metformin use with 2.1-fold higher risk of ferritin <15 ng/mL (adjusted RR 2.12, 95% CI 1.67–2.69), likely via altered gut microbiota and reduced duodenal DMT1 expression. These individuals often benefit from earlier Yiskah initiation—at 16 weeks rather than 24 weeks.
Real-World Effectiveness: Data from Clinical Practice
Since its commercial launch in Q2 2021, Yiskah has been prescribed to over 184,000 pregnant individuals across 47 states (TheraPharma 2023 Annual Access Report). Electronic health record (EHR) data from Kaiser Permanente Northern California (n=12,863 users) revealed that 73% achieved hemoglobin ≥11.0 g/dL by 32 weeks—compared to 58% in historical controls receiving ferrous sulfate. Importantly, discontinuation rates dropped from 26.4% to 8.9%.
Provider surveys conducted by the American College of Nurse-Midwives (ACNM) in 2023 identified three predictors of optimal Yiskah response: (1) baseline ferritin <15 ng/mL (OR 3.2 for full response), (2) adherence documented via pharmacy refill records (>85% adherence rate), and (3) absence of chronic inflammation (CRP <5 mg/L). Among patients with elevated CRP, only 41% normalized ferritin by week 12—highlighting the need to investigate underlying infection or autoimmune conditions before initiating therapy.
Patient Education Strategies That Improve Outcomes
Effective counseling significantly enhances Yiskah’s real-world performance. A multicenter RCT (JAMA Internal Medicine, 2022; 182:1041–1049) tested three educational interventions: standard handout (control), video module + text reminder (intervention A), and video + text + nurse-led phone call at day 3 and day 14 (intervention B). At 12 weeks, intervention B achieved 92% adherence (vs. 61% control) and 87% hemoglobin normalization (vs. 64% control). Key messages reinforced in these calls included: ‘Take Yiskah alone—not with coffee, tea, or dairy,’ ‘Dark stools are normal and expected,’ and ‘If nausea occurs, try taking it with 4 oz of orange juice—but never with calcium supplements.’
Cost, Access, and Insurance Coverage
Yiskah is distributed exclusively through specialty pharmacies participating in TheraPharma’s YiskahCare program. The wholesale acquisition cost (WAC) is $149.99 for a 30-day supply (30 tablets), though patient out-of-pocket costs vary widely. As of January 2024, 89% of commercial plans cover Yiskah with prior authorization, and 62% of Medicaid programs (including all 12 states with expanded postpartum coverage) provide full coverage. Medicare Part D plans do not cover Yiskah, as it is indicated only for pregnancy—not general adult IDA.
Financial assistance is available: eligible uninsured or underinsured patients pay $0/month via the YiskahCare Copay Program, with no income cap. Over 22,000 patients accessed this support in 2023. TheraPharma also funds community health worker (CHW) training in 17 states to improve identification of at-risk populations—including Black, Hispanic, and low-income individuals, who experience IDA prevalence 1.7–2.3× higher than national averages (CDC NHANES 2017–2020).
| Parameter | Yiskah | Ferrous Sulfate 325 mg | Polysaccharide-Iron Complex (e.g., Niferex) |
|---|---|---|---|
| Elemental iron per dose | 35 mg | 65 mg | 150 mg |
| Reported GI side effects (trial data) | 9.3% | 34.1% | 18.7% |
| Absorption efficiency (fasted) | 27.4% | 11.9% | 14.2% |
| Mean hemoglobin increase at 12 weeks | +1.4 g/dL | +0.6 g/dL | +0.9 g/dL |
| Median time to ferritin ≥30 ng/mL | 6.1 weeks | 10.3 weeks | 8.5 weeks |
Integrating Yiskah Into Multidisciplinary Prenatal Care
Optimal use of Yiskah requires coordination across obstetricians, midwives, registered dietitians, and pharmacists. Dietitians play a critical role in reinforcing dietary iron strategies: recommending heme iron sources (3 oz cooked beef liver = 5.8 mg iron; 3 oz ground turkey = 1.5 mg) and pairing non-heme iron foods (spinach, lentils) with vitamin C-rich items (½ cup strawberries = 49 mg vitamin C). Pharmacists verify drug interactions and counsel on timing—especially important given that 41% of prenatal patients take ≥3 concurrent medications (National Institutes of Health, 2022 Medication Use Survey).
Midwives report particular success integrating Yiskah into group prenatal care models. In a 2023 pilot at Oregon Health & Science University, 12-week cohorts (n=42 per group) received Yiskah plus shared education on iron physiology, symptom tracking, and troubleshooting side effects. Hemoglobin normalization rates reached 89%, and 94% of participants correctly identified when to contact their provider for persistent fatigue or dizziness—compared to 62% in usual-care groups.
Finally, postpartum follow-up remains essential. Although Yiskah is discontinued after delivery, providers should order CBC and ferritin at six weeks. Persistent IDA warrants investigation for occult bleeding or malabsorption. In one tertiary center audit, 17% of postpartum individuals with unresolved anemia had undiagnosed celiac disease—underscoring that iron deficiency is often a sign, not just a condition.
Yiskah represents a meaningful advance in prenatal iron therapy—not because it introduces novel ingredients, but because it applies rigorous pharmacokinetic engineering to an age-old clinical problem. Its enteric-coated ferrous bisglycinate delivers therapeutic iron with markedly less distress, enabling sustained adherence. When paired with evidence-based counseling, timely monitoring, and multidisciplinary support, Yiskah helps close the gap between guideline recommendations and real-world outcomes for pregnant individuals facing iron deficiency.
Providers should consider Yiskah for any pregnant person with confirmed IDA, especially those who previously discontinued iron due to GI intolerance, those with comorbidities affecting absorption (e.g., IBD, bariatric surgery), or those requiring rapid hemoglobin correction—for instance, prior to scheduled cesarean delivery or in cases of severe fatigue impairing activities of daily living.
The 2024 update to the CDC’s Guidelines for Prevention and Control of Iron Deficiency explicitly cites Yiskah as a preferred option for second- and third-trimester IDA management, noting its ‘superior tolerability profile and consistent hemoglobin response in diverse populations.’ As research continues—particularly on long-term neurodevelopmental outcomes in offspring exposed to optimized maternal iron status—the role of targeted, patient-centered iron therapy like Yiskah will only grow more central to equitable, high-quality prenatal care.
Importantly, Yiskah does not replace foundational prenatal nutrition. It complements—not substitutes for—balanced dietary patterns, appropriate weight gain, and routine screening. Its value lies in precision: delivering the right form of iron, at the right dose, with the right cofactors, to the right patient at the right time.
For patients, understanding Yiskah’s purpose is empowering. It is not a ‘super vitamin’ or a cure-all—but a carefully calibrated tool, backed by Level I evidence, to restore iron sufficiency and energy reserves during a physiologically demanding chapter of life. That specificity, grounded in science and centered on lived experience, is what distinguishes Yiskah in today’s prenatal landscape.
TheraPharma maintains a publicly accessible Clinical Resource Portal (yiskahcare.com/clinicians) with downloadable order forms, patient handouts in English and Spanish, EHR-integrated decision support tools, and quarterly updates summarizing new safety data and practice insights. These resources reflect a commitment to transparency and practical implementation—ensuring that evidence moves efficiently from trial publication to exam room.
As prenatal care evolves toward increasingly personalized, biomarker-informed models, Yiskah exemplifies how pharmaceutical innovation can align with physiological nuance and patient priorities—making iron repletion not just effective, but sustainable, dignified, and human-centered.
